Post‐authorization safety study to assess the risk of diabetic ketoacidosis among type 2 diabetes mellitus patients treated with ertugliflozin compared to patients treated with other antihyperglycaemic agents in a Medicare and Medicaid population
Diabetic Medicine · 2026
DOI: 10.1111/dme.70208 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Diabetic Medicine, 2026. Verfasst von Ashish Rai und 21 weiteren Autor:innen. Beteiligte Einrichtung: Harvard Medical School, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Hypoglycemic Agents, Diabetic Ketoacidosis, Bridged Bicyclo Compounds, Heterocyclic. Die Arbeit nennt 30 Literaturangaben. Gefördert von: Pfizer Inc US, Merck Sharp & Dohme LLC.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aims
To evaluate diabetic ketoacidosis (DKA) risk among new users of ertugliflozin versus sulfonylureas (SU) or thiazolidinediones (TZD) and incretin‐based drugs in patients with type 2 diabetes.
Methods
We used Medicare and Medicaid fee‐for‐service adjudicated claims within the Innovation in Medical Evidence and Development Surveillance network to identify three new‐user cohorts: (1) ertugliflozin; (2) SU/TZD; and (3) incretin‐based drugs. The outcome was a principal hospital discharge diagnosis for DKA. Adjusted hazard ratios (HRs) were estimated after 1:1 propensity score (PS) matching, separately for ertugliflozin vs. SU/TZD and vs. incretin‐based drugs. Subgroup analyses were performed based on baseline insulin use.
Results
After PS matching, baseline characteristics were similarly distributed in each cohort. For ertugliflozin ( n = 42,907) vs. SU/TZD ( n = 42,907), the incidence rates of DKA per 1000 person‐years (PY) were 2.95 and 1.49, respectively. For ertugliflozin ( n = 42,247) vs. incretin‐based drugs ( n = 42,247), the incidence rates of DKA per 1000 PY were 2.76 and 1.06, respectively. For ertugliflozin vs. SU/TZD, the HR [95% confidence interval (CI)] was 1.88 [1.17–3.02]; in non‐insulin users, 2.34 [1.27–4.31]; and in insulin users, 1.17 [0.54–2.52]. For ertugliflozin vs. incretin‐based drugs, the HR [95% CI] was 2.40 [1.40–4.11]; in non‐insulin users, 2.84 [1.42–5.66]; and in insulin users, 1.87 [0.79–4.46].
Conclusions
Ertugliflozin was associated with a higher risk of DKA relative to comparators. HRs were higher among new users with no‐concomitant insulin use than those with concomitant insulin use. Results were consistent with prior SGLT2i data and highlighted the importance of caution by both patients and physicians.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Harvard Medical School, Boston, Massachusetts, USA.
- Department of Population Medicine, Harvard Pilgrim Health Care Institute, Boston, Massachusetts, USA.
- Reagan-Udall Foundation for the FDA, Washington, DC, USA.
- Evidence to Practice, Durham, North Carolina, USA.
- Optum Life Sciences, Boston, Massachusetts, USA.
- HealthPartners Institute, Bloomington, Minnesota, USA.
ORCID-Profile: Ashish Rai, Ting-Ying Huang, Brandon Diessner, Djeneba Audrey Djibo, Ravi Shankar, Precious Ejelonu, Robert Frederich, Urszula Masiukiewicz, Sengwee Toh
Förderung
- Pfizer Inc US
- Merck Sharp & Dohme LLC
Zitieren
APA
Rai, A., Marshall, J., Nandyala, S., Her, M., Agan, A. A., Huang, T. Y., Rodriguez-Watson, C., Clary, A., Diessner, B., Nolan, M. B., Djibo, D. A., DeVries, A., Daniels, K., Zhang, X., Wang, T., Gantz, I., Shankar, R., Zale, M. M., Ejelonu, P., …, & Toh, S. (2026). Post‐authorization safety study to assess the risk of diabetic ketoacidosis among type 2 diabetes mellitus patients treated with ertugliflozin compared to patients treated with other antihyperglycaemic agents in a Medicare and Medicaid population. Diabetic Medicine. https://doi.org/10.1111/dme.70208
Vancouver
Rai A, Marshall J, Nandyala S, Her M, Agan AA, Huang TY, et al. Post‐authorization safety study to assess the risk of diabetic ketoacidosis among type 2 diabetes mellitus patients treated with ertugliflozin compared to patients treated with other antihyperglycaemic agents in a Medicare and Medicaid population. Diabetic Medicine. 2026. doi:10.1111/dme.70208
BibTeX
@article{Rai2026,
author = {Rai, Ashish and Marshall, James and Nandyala, Sampada and Her, Meg and Agan, Anna A and Huang, Ting-Ying and Rodriguez-Watson, Carla and Clary, Alecia and Diessner, Brandon and Nolan, Margaret B and Djibo, Djeneba Audrey and DeVries, Andrea and Daniels, Kimberly and Zhang, Xiao and Wang, Tongtong and Gantz, Ira and Shankar, Ravi and Zale, Melissa MacCoy and Ejelonu, Precious and Frederich, Robert and Masiukiewicz, Urszula and Toh, Sengwee},
title = {Post‐authorization safety study to assess the risk of diabetic ketoacidosis among type 2 diabetes mellitus patients treated with ertugliflozin compared to patients treated with other antihyperglycaemic agents in a Medicare and Medicaid population},
journal = {Diabetic Medicine},
year = {2026},
doi = {10.1111/dme.70208}
}
EUVIMED